November 28, 2016 - By Adrian Mccoy · 0 Comments
The stock of Bristol Myers Squibb Company (NYSE:BMY) registered a decrease of 0.04% in short interest. BMY’s total short interest was 13.13 million shares in November as published by FINRA. Its down 0.04% from 13.14M shares, reported previously. With 12.14 million shares average volume, it will take short sellers 1 days to cover their BMY’s short positions. The short interest to Bristol Myers Squibb Company’s float is 0.85%. The stock increased 0.41% or $0.23 during the last trading session, hitting $56.98. About 45 shares traded hands. Bristol-Myers Squibb Co (NYSE:BMY) has declined 19.33% since April 25, 2016 and is downtrending. It has underperformed by 25.34% the S&P500.
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has a market cap of $95.61 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 28.38 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.
Insitutional Activity: The institutional sentiment increased to 1.13 in Q2 2016. Its up 0.19, from 0.94 in 2016Q1. The ratio is positive, as 47 funds sold all Bristol-Myers Squibb Co shares owned while 542 reduced positions. 84 funds bought stakes while 472 increased positions. They now own 1.19 billion shares or 3.56% less from 1.23 billion shares in 2016Q1.
Frontier Cap Management Limited Liability has 0.01% invested in the company for 17,402 shares. Nationwide Fund Advsrs has invested 0.54% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Interocean Cap Ltd Llc has invested 0.07% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Rathbone Brothers Public Limited Liability Co holds 0.28% or 69,686 shares in its portfolio. Bollard Gp Limited Com has 0.86% invested in the company for 170,663 shares. Jane Street Ltd Liability Corporation last reported 0.01% of its portfolio in the stock. Zweig accumulated 299,642 shares or 2.25% of the stock. Segall Bryant Hamill Ltd reported 53,151 shares or 0.1% of all its holdings. Smith Moore & Company holds 0.3% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 9,818 shares. Heritage Investors Mngmt Corp reported 100,420 shares or 0.56% of all its holdings. Davidson And Garrard has 46,431 shares for 0.84% of their US portfolio. Clarkston Prns Lc reported 34,600 shares or 0.13% of all its holdings. Mcmillion Cap Management last reported 3.62% of its portfolio in the stock. Fairfield Bush & accumulated 12,071 shares or 0.31% of the stock. Chatham Cap Grp, a Georgia-based fund reported 7,870 shares.
Insider Transactions: Since June 14, 2016, the stock had 0 insider purchases, and 5 selling transactions for $6.86 million net activity. 21,600 Bristol-Myers Squibb Co (NYSE:BMY) shares with value of $1.23M were sold by ANDREOTTI LAMBERTO. Elicker John E sold $859,219 worth of Bristol-Myers Squibb Co (NYSE:BMY) on Tuesday, June 14.
Out of 16 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 5 rate it a “Buy”, 3 “Sell”, while 8 “Hold”. This means 31% are positive. $80 is the highest target while $52 is the lowest. The $68.90 average target is 20.92% above today’s ($56.98) stock price. Bristol-Myers Squibb Company has been the topic of 34 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Jefferies maintained the stock with “Hold” rating in Thursday, August 27 report. Deutsche Bank maintained it with “Hold” rating and $52 target price in Friday, October 28 report. As per Thursday, July 14, the company rating was maintained by Jefferies. The firm has “Buy” rating given on Tuesday, September 29 by UBS. The rating was maintained by Barclays Capital on Friday, April 29 with “Equal Weight”. The stock has “Neutral” rating given by Hilliard Lyons on Monday, May 23. The stock of Bristol-Myers Squibb Co (NYSE:BMY) earned “Buy” rating by UBS on Friday, April 29. The firm has “Underweight” rating by Piper Jaffray given on Monday, August 24. The firm has “Equal Weight” rating by Barclays Capital given on Tuesday, December 1. The firm has “Market Perform” rating given on Monday, January 25 by BMO Capital Markets.
Bristol-Myers Squibb Company, incorporated on August 11, 1933, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. The Company’s products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy